Literature DB >> 28683166

Multibiomarker analysis in patients with acute myocardial infarction.

Christiana Schernthaner1, Michael Lichtenauer1, Bernhard Wernly1, Vera Paar1, Rudin Pistulli2, Ilonka Rohm2, Christian Jung3, Hans-Reiner Figulla2, Attila Yilmaz2, Janne Cadamuro4, Elisabeth Haschke-Becher4, John Pernow5, Paul Christian Schulze2, Uta C Hoppe1, Daniel Kretzschmar2.   

Abstract

BACKGROUND: Novel biomarkers representing different pathobiological pathways and their role in patients with acute myocardial infarction (AMI) were studied.
METHODS: We retrospectively analysed serum levels of soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR), heart-type fatty acid-binding protein (H-FABP) and plasma fetuin A in blood of patients with AMI (STEMI, n = 61; NSTEMI, n = 57) compared to controls with excluded coronary artery disease (n = 76). Furthermore, detailed correlation analysis was performed.
RESULTS: Compared with controls, in patients with STEMI and NSTEMI higher levels expressed as median of sST2 in pg/mL (STEMI: 13210·9, NSTEMI: 11989·1, control: 5248; P < 0·001), GDF-15 in pg/mL (STEMI: 818·8, NSTEMI 677·5, control 548·6; P < 0·001), suPAR in pg/mL (STEMI: 3461·1, NSTEMI: 3466·7, control: 2463·6; P < 0·001), H-FABP in ng/mL (STEMI: 5·8, NSTEMI: 5·4, control: 0·0; P < 0·001) and lower plasma fetuin A levels in μg/mL (STEMI: 95, NSTEMI: 54, control: 116·6; P < 0·001) were detected. Correlation analysis found clinical and biochemical parameters such as ejection fraction, length of hospital stay, creatine kinase, NT-proBNP and hs Troponin T levels as well as inflammatory markers (CRP, leucocytes) to be significantly correlated with novel biomarkers.
CONCLUSION: Plasma levels of novel biomarkers were significantly elevated (sST2, GDF-15, H-FABP, suPAR) or inversely downregulated (fetuin A) in patients with AMI compared to a control group with excluded coronary artery disease. Significant correlations with various clinical parameters and standard biochemical markers were found.
© 2017 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Fetuin A; H-FABP; acute myocardial infarction; biomarkers; heart failure; left ventricular remodelling; risk stratification; sST2, GDF-15; suPAR

Mesh:

Substances:

Year:  2017        PMID: 28683166     DOI: 10.1111/eci.12785

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  16 in total

1.  Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.

Authors:  David D Berg; Christian T Ruff; Petr Jarolim; Robert P Giugliano; Francesco Nordio; Hans J Lanz; Michele F Mercuri; Elliott M Antman; Eugene Braunwald; David A Morrow
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

2.  Higher serum sST2 is associated with increased left atrial low-voltage areas and atrial fibrillation recurrence in patients undergoing radiofrequency ablation.

Authors:  Jiali Fan; Yuan Li; Qing Yan; Wenhuan Wu; Pan Xu; Lu Liu; Chunhong Luan; Juanli Zhang; Qiangsun Zheng; Jiahong Xue
Journal:  J Interv Card Electrophysiol       Date:  2022-02-17       Impact factor: 1.759

3.  Biomechanical stress in myocardial infarctions: can endothelin-1 and growth differentiation factor 15 serve as immunohistochemical markers?

Authors:  M Falk; R Huhn; F Behmenburg; St Ritz-Timme; F Mayer
Journal:  Int J Legal Med       Date:  2017-11-18       Impact factor: 2.686

Review 4.  Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis.

Authors:  Xiao-Dong Ye; Yi He; Sheng Wang; Gordon T Wong; Michael G Irwin; Zhengyuan Xia
Journal:  Acta Pharmacol Sin       Date:  2018-05-17       Impact factor: 6.150

5.  Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls.

Authors:  Peter Jirak; Rudin Pistulli; Michael Lichtenauer; Bernhard Wernly; Vera Paar; Lukas J Motloch; Richard Rezar; Christian Jung; Uta C Hoppe; P Christian Schulze; Daniel Kretzschmar; Rüdiger C Braun-Dullaeus; Tarek Bekfani
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

6.  Carcinoid heart disease involving the left heart: a case report and biomarker analysis.

Authors:  Michael Lichtenauer; Tristan Pichler; Sarah Eder; Moritz Mirna; Theresa Magnes; Bernhard Wernly; Vera Paar; Christian Jung; Erika Prinz; Rainald Seitelberger; Uta C Hoppe
Journal:  ESC Heart Fail       Date:  2019-01-08

7.  GDF-15 in solid vs non-solid treatment-naïve malignancies.

Authors:  Henrike Arfsten; Anna Cho; Claudia Freitag; Markus Raderer; Georg Goliasch; Philipp E Bartko; Raphael Wurm; Guido Strunk; Heinz Gisslinger; Christine Marosi; Gabriela Kornek; Christoph Zielinski; Martin Hülsmann; Noemi Pavo
Journal:  Eur J Clin Invest       Date:  2019-09-26       Impact factor: 4.686

8.  Pericardial fluid levels of growth differentiation factor 15 in patients with or without coronary artery disease: a prospective study.

Authors:  Zhize Yuan; Haiqing Li; Yanjun Sun; Jiapei Qiu; Hong Xu; Jun Liu; Mi Zhou; Anqing Chen; Xiaofeng Ye; Zhe Wang; Qiang Zhao
Journal:  Ann Transl Med       Date:  2020-02

Review 9.  Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges.

Authors:  Ioan Tilea; Andreea Varga; Razvan Constantin Serban
Journal:  Diagnostics (Basel)       Date:  2021-05-15

10.  Therapeutic and Diagnostic Value of Caspase-12 and Study of Growth Differentiation Factor-15 in Patients with Acute Myocar-dial Infarction.

Authors:  Changqing Sun; Xiulin Li; Daoqing Wang; Liming Wang
Journal:  Iran J Public Health       Date:  2020-12       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.